David M. Ross

7.0k total citations · 1 hit paper
143 papers, 3.0k citations indexed

About

David M. Ross is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, David M. Ross has authored 143 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Hematology, 106 papers in Genetics and 42 papers in Rheumatology. Recurrent topics in David M. Ross's work include Chronic Myeloid Leukemia Treatments (91 papers), Chronic Lymphocytic Leukemia Research (56 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (51 papers). David M. Ross is often cited by papers focused on Chronic Myeloid Leukemia Treatments (91 papers), Chronic Lymphocytic Leukemia Research (56 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (51 papers). David M. Ross collaborates with scholars based in Australia, United States and Germany. David M. Ross's co-authors include Timothy P. Hughes, Susan Branford, David T Yeung, John F. Seymour, Andrew Grigg, Anthony K. Mills, Anthony P. Schwarer, Robin Filshie, Deborah L. White and Christopher Arthur and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

David M. Ross

129 papers receiving 3.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

2013 508 citations David M. Ross, Susan Branford et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David M. Ross	2.6k	2.1k	1.2k	482	408	143	3.0k
Agnès Guerci	1.9k 0.8×	1.3k 0.6×	666 0.6×	247 0.5×	463 1.1×	49	2.1k
Éric Lippert	1.3k 0.5×	1.4k 0.7×	603 0.5×	278 0.6×	968 2.4×	102	2.2k
Jan Samuelsson	1.9k 0.7×	1.9k 0.9×	682 0.6×	271 0.6×	1.2k 2.8×	75	2.8k
H. Pralle	1.3k 0.5×	869 0.4×	410 0.3×	284 0.6×	275 0.7×	65	1.8k
Yana Pikman	1.8k 0.7×	2.0k 1.0×	711 0.6×	279 0.6×	1.5k 3.8×	41	2.7k
Guillermo Garcia‐Manero	1.3k 0.5×	834 0.4×	271 0.2×	248 0.5×	532 1.3×	40	1.8k
William Mietlowski	858 0.3×	695 0.3×	452 0.4×	500 1.0×	347 0.9×	32	1.8k
Joanna Góra‐Tybor	594 0.2×	733 0.3×	186 0.2×	218 0.5×	291 0.7×	82	1.2k
Angelo Guerrasio	938 0.4×	547 0.3×	145 0.1×	255 0.5×	787 1.9×	105	1.7k
Andrey Zaritskey	429 0.2×	505 0.2×	234 0.2×	248 0.5×	202 0.5×	66	1.0k

Countries citing papers authored by David M. Ross

Since Specialization

Citations

This map shows the geographic impact of David M. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Ross more than expected).

Fields of papers citing papers by David M. Ross

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Ross. The network helps show where David M. Ross may publish in the future.

Co-authorship network of co-authors of David M. Ross

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Ross. A scholar is included among the top collaborators of David M. Ross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Ross. David M. Ross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ross, David M., et al.. (2025). Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities. Cancers. 17(18). 3033–3033.

Bose, Prithviraj, Hsin‐An Hou, Wojciech Homenda, et al.. (2024). Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 483–483. 3 indexed citations

Robinson, Nirmal, Monika Kutyna, Kelly Lim, et al.. (2024). High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine. Blood. 144(Supplement 1). 1817–1817. 2 indexed citations

Hiwase, Devendra, David M. Ross, David T Yeung, et al.. (2024). Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine. Blood. 144(Supplement 1). 1006–1006. 2 indexed citations

Lim, Kelly, Winnie L. Kan, Pramod C. Nair, et al.. (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS ONE. 19(9). e0310641–e0310641.

Nair, Pramod C., Jacob Piehler, Denis Tvorogov, et al.. (2023). Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches. Blood Cancer Discovery. 4(5). 352–364. 12 indexed citations

Erber, Wendy N., et al.. (2023). Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry. Pathology. 56(1). 75–80. 4 indexed citations

Ross, David M., Donal P. McLornan, Krisstina Gowin, et al.. (2022). Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis. American Journal of Hematology. 97(11). 1464–1477. 7 indexed citations

Samaraweera, Saumya E., Tatjana Geukens, Débora A. Casolari, et al.. (2022). Novel modes of MPL activation in triple-negative myeloproliferative neoplasms. Pathology. 55(1). 77–85. 1 indexed citations

10.

Hughes, Elizabeth, David M. Ross, Matthew Greenwood, et al.. (2022). Sensitive Measurement of Minimal Residual Disease in Blood by HAT-PCR. Journal of Molecular Diagnostics. 24(6). 632–641. 2 indexed citations

11.

Radich, Jerald P., Andreas Hochhaus, Tamás Masszi, et al.. (2021). Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 35(5). 1344–1355. 47 indexed citations

12.

Martin, Hilary, Shahid Ullah, Ganessan Kichenadasse, et al.. (2021). Predicting chemotherapy‐induced menopause using baseline and post‐chemotherapy anti‐Müllerian hormone levels: Results of a pilot study. Cancer Reports. 4(3). e1342–e1342. 3 indexed citations

13.

Mascarenhas, John, Francesco Passamonti, Kate Burbury, et al.. (2021). The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances. 6(4). 1162–1174. 16 indexed citations

14.

Irani, Yazad, Amy Hughes, Jade Clarson, et al.. (2020). Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology. 191(3). 433–441. 54 indexed citations

15.

Lasica, Masa, Abbey Willcox, Kate Burbury, et al.. (2019). The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leukemia & lymphoma. 60(7). 1796–1802. 15 indexed citations

16.

Tvorogov, Denis, Danièl Thomas, Nicholas P. D. Liau, et al.. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances. 4(11). eaat3834–eaat3834. 41 indexed citations

17.

Hahn, Christopher N, Milena Babic, Jinghua Feng, et al.. (2017). Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms. Blood. 130. 492–492. 3 indexed citations

18.

Shanmuganathan, Naranie, Susan Branford, David T Yeung, et al.. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. Blood. 130. 1621–1621. 1 indexed citations

19.

Latham, Susan, David M. Ross, Elizabeth Hughes, et al.. (2016). BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. Journal of Clinical Pathology. 69(9). 817–821. 5 indexed citations

20.

Hughes, Timothy P. & David M. Ross. (2016). Moving treatment-free remission into mainstream clinical practice in CML. Blood. 128(1). 17–23. 227 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact